Rimeporide as a first- in-class NHE-1 inhibitor : Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy

MLA

Previtali, Stefano C., et al. Rimeporide as a First- in-Class NHE-1 Inhibitor : Results of a Phase Ib Trial in Young Patients with Duchenne Muscular Dystrophy. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1235087157&authtype=sso&custid=ns315887.

APA

Previtali, S. C., Gidaro, T., Diaz-Manera, J., Zambon, A., Carnesecchi, S., Roux-Lombard, P., Spitali, P., Signorelli, M., Al-Khalili Szigyarto, C., Johansson, C., Gray, J., Labolle, D., Thome, F. P., Pitchforth, J., Domingos, J., & Muntoni, F. (2020). Rimeporide as a first- in-class NHE-1 inhibitor : Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy.

Chicago

Previtali, Stefano C., Teresa Gidaro, Jordi Diaz-Manera, Alberto Zambon, Stephanie Carnesecchi, Pascale Roux-Lombard, Pietro Spitali, et al. 2020. “Rimeporide as a First- in-Class NHE-1 Inhibitor : Results of a Phase Ib Trial in Young Patients with Duchenne Muscular Dystrophy.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1235087157&authtype=sso&custid=ns315887.